Skip to content

Bathing Additives in Pediatric Atopic Dermatitis

Bathing Additives in Management of Pediatric Atopic Dermatitis

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02582788
Enrollment
10
Registered
2015-10-21
Start date
2015-10-31
Completion date
2018-04-30
Last updated
2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Atopic

Brief summary

The current clinical guidelines for management of atopic dermatitis now recommend bleach baths. This requires simply the addition of regular household bleach to twice-weekly baths. At the Mayo Clinic, dilute acetic acid (vinegar) has been recommended for decades in wet wraps to treat patients hospitalized for their atopic dermatitis. However, this practice has not been widely adopted in the pediatric dermatology community. Will the use of dilute acetic acid (vinegar) in twice weekly baths help manage atopic dermatitis in pediatric patients as well as, or better than, the current accepted guidelines?

Interventions

OTHERBathing Additive

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

1. Patients from 6 months to 17 years of age 2. Currently residing in US. 3. Follow up visits at 1 month, 3 months and 6 months after initiation of treatment in study (Figure 1). 4. Last follow-up at 1 year in clinic or via written mailed-out survey. 5. Diagnosis of atopic dermatitis AND 1. Have active signs of bacterial skin infection OR 2. Any documented suspected history of bacterial skin infection (weeping, crusting, and/or pustules on exam), OR 3. Prescription for oral antibiotics for skin infection in the past 6 months from any provider). OR 4. Have been prescribed bleach baths as part of an atopic dermatitis skin care regimen.

Exclusion criteria

1. Superficial skin infection without diagnosis of atopic dermatitis 2. Lack of in-clinic follow up assessment at 6 months

Design outcomes

Primary

MeasureTime frame
EASI score at 6 months6 months

Secondary

MeasureTime frame
Courses of antibiotics required1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026